N-of-1 CRISPR trial ends with a death as nonprofit digs into what happened

Zachary Brennan

Senior Editor

Almost two months after the nonprofit Cure Rare Disease received FDA clearance to administer its first-in-human CRISPR therapeutic for Duchenne muscular dystrophy, the nonprofit announced …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

N-of-1 CRISPR trial ends with a death as nonprofit digs into what happened

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Sanofi faces $250M charge after J&J-partnered vaccine flunks late-stage test

Kennedy is confirmed to lead HHS, putting anti-vaccine advocate and drug industry skeptic atop US health programs

After helping build AlphaFold, a 34-year-old first-time CEO launches his own AI biotech with $50M

Newleos, a new biotech with $93.5M, repurposes Roche's experimental CNS drugs

Neumora shakes up C-suite a month after depression drug fails first Phase 3 trial

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

N-of-1 CRISPR tri­al ends with a death as non­prof­it digs in­to what hap­pened

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

N-of-1 CRISPR trial ends with a death as nonprofit digs into what happened